- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04979052
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
November 2, 2023 updated by: Radboud University Medical Center
Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia
A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety and efficacy of rIFN-y treatment in patiens with candidemia.
Study Overview
Detailed Description
A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety and efficacy of rIFN-y treatment in patiens with candidemia.
Patients will be randomized 1:1 between intervention (rIFN-y immunotherapy, subcutaneous dose of 100miicrogram thrice weekly for two weeks or until hospital discharge) in addition to standard of care versus controls (standard of care).
Standard of care antifungal therapy is according to ESCMID/EFISG (Europe) or IDSA (US) guidelines.
We will assess the effect on clinical outcome and investigate relevant biomarkers that can guide this immunotherapeutic approach.
Study Type
Interventional
Enrollment (Estimated)
200
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Frank vd Veerdonk, Dr.
- Phone Number: 0031243618819
- Email: frank.vandeveerdonk@radboudumc.nl
Study Locations
-
-
-
Frankfurt am main, Germany, 60590
- Recruiting
- Klinikum Der Johann Wolfgang Von Goethe Universitaet
-
Contact:
- Maria Vehreschild, Prof. Dr.
-
-
-
-
-
Athens, Greece, 11528
- Recruiting
- Hellenic Institute for the Study of Sepsis (HISS)
-
Contact:
- Evangelos Giamarellos-Bourboulis, Prof. Dr.
-
-
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6525 GA
- Recruiting
- Radboudumc
-
Contact:
- Frank vd Veerdonk, Prof. Dr.
-
-
-
-
-
Cluj-Napoca, Romania, 400348
- Recruiting
- Universitatea de Medicina si Farmacie luliu Hatieganu
-
Contact:
- Mihaela Sorina Lupse, Dr.
-
-
-
-
-
Lausanne, Switzerland, 1005
- Not yet recruiting
- Centre Hospitalier Universitaire Vaudois
-
Contact:
- Thierry Calandra, Prof. Dr.
-
-
-
-
North Carolina
-
Durham, North Carolina, United States, 27708
- Not yet recruiting
- Duke University
-
Contact:
- John R. Perfect, Dr.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Males or non-pregnant females (who must agree to use barrier methods of contraception during the study therapy period, women of childbearing age must have a negative urine pregnancy or serum test at baseline).
- Subjects who are 18 years of age or older.
- Subjects with at least one positive blood culture isolation of Candida species from a specimen drawn within 120 hours prior to study entry.
Subjects who have clinical evidence of infection sometime within 120 hours prior to enrolment, including at least one of the following:
- Temperature >37.8 ˚C on two occasions at least four hours apart or one measurement > 38.2 ˚C
- Systolic blood pressure <90 or a >30 mmHg decrease in systolic blood pressure from the subject's normal baseline or the need for vassopressive therapy.
- Signs of inflammation (swelling, heat, erythema, purulent drainage) from a site infected with Candida (e.g. joint, skin, eye, bone, oesophagus).
- Radiologic findings of invasive candidiasis.
- Subject or their legal representative must sign a written informed consent form.
In case a patient eligible to participate in this study is incapacitated and as such unable to personally provide informed consent, a written consent form must be signed by their legal representative.
- Only incapacitated patients that can be expected to regain the capability to consent will be included in this study. In this case, informed consent will be discussed personally with the study participant after recovery.
- The inclusion of incapacitated subjects will only be performed under the above conditions in a country in which such an approach is legal and deemed ethically acceptable.
Exclusion Criteria:
- Subjects with a history of allergy or intolerance to rIFN-γ,or any other IMP ingredient or with a history of immediate type hypersensitivity to latex/rubber.
- Subjects with a history of documented epileptic seizures.
- Subjects with severe liver failure ((>5x upper limit AST or ALT or impaired synthesis of proteins such as coagulation factors manifested by increased prothrombin time).
- Treatment with heterologous serum proteins, or immunological preparations such as vaccines, toxins, serums and allergens within three days before trial enrolment.
- Women who are pregnant or lactating.
- Subjects who are unlikely to survive more than 24 hours.
- Subjects who have failed previous systemic antifungal therapy for the Candida spp.
infection which is being studied.
- Subjects who have received more than 120 hours of systemic antifungal therapy for the current episode, within 120 hours prior to study entry.
- With respect to incapacitated subjects:
- Any patient that is deemed incapable of personally providing informed consent due to a neurodegenerative disease, genetic syndrome, and/or perinatal asphyxia, will not be eligible for inclusion in this trial.
- Any incapacitated subject that is not expected to recover to a point where they will personally be able to provide informed consent will not be eligible for inclusion in this trial. Patients with renal failure or dialysis do not have a contraindication for treatment with rIFN-y and can be included in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Interferon-Gamma
Recombinant Interferon-Gamma 1b combined with standard therapy
|
100 microgram per day, three times a week, subcutaneous.
The duration of the treatment is twelve days or until hospital discharge.
Other Names:
|
No Intervention: Standard of care
Standard of care antifungal therapy according tot ESCMID/EFISG (Europe) or ISDA (US) guidelines.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to first negative blood culture
Time Frame: Day 14
|
Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to treatment success
Time Frame: Day 14
|
microbiological eradication of Candida from the blood and any other site of infection; resolution of fever; resolution of other diagnostic variables, such as imaging results, where applicable; and no new signs of infection.
The time at which all the variables are met is defined as the date of resolution of infection.
|
Day 14
|
Percentage of patients with mycological outcomes
Time Frame: through intervention completion, an average at day 11 and 2 and 4 weeks after intervention completion
|
through intervention completion, an average at day 11 and 2 and 4 weeks after intervention completion
|
|
Percentage of patients with treatment success
Time Frame: through intervention completion, an average at day 11 and 2 and 4 weeks after intervention completion
|
through intervention completion, an average at day 11 and 2 and 4 weeks after intervention completion
|
|
Overall survival
Time Frame: Study day 28
|
Study day 28
|
|
Number of patients with Treatment Emergent Adverse Events (TEAEs).
Time Frame: Study day 49
|
Study day 49
|
|
Sequential Organ Failure Assessment (SOFA) score
Time Frame: Study day 14
|
Study day 14
|
|
Adverse events
Time Frame: Study day 14
|
Study day 14
|
|
Body weight
Time Frame: Study day 49
|
kg
|
Study day 49
|
BMI
Time Frame: Study day 49
|
kg/m^2
|
Study day 49
|
Prealbumin
Time Frame: Study day 49
|
mg/dl
|
Study day 49
|
Total lymphocytes
Time Frame: Study day 49
|
10^9/L
|
Study day 49
|
Cholesterol
Time Frame: Study day 49
|
mmol/L
|
Study day 49
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Frank vd Veerdonk, Dr., Radboud university medical center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 31, 2022
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
January 1, 2025
Study Registration Dates
First Submitted
November 9, 2020
First Submitted That Met QC Criteria
July 16, 2021
First Posted (Actual)
July 27, 2021
Study Record Updates
Last Update Posted (Estimated)
November 3, 2023
Last Update Submitted That Met QC Criteria
November 2, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Systemic Inflammatory Response Syndrome
- Inflammation
- Bacterial Infections and Mycoses
- Sepsis
- Mycoses
- Invasive Fungal Infections
- Fungemia
- Candidiasis
- Candidiasis, Invasive
- Candidemia
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Interferons
- Interferon-gamma
Other Study ID Numbers
- HDM-FUN-Candidemia
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Candidemia
-
Taipei Medical University WanFang HospitalCompletedNon-albicans CandidemiaTaiwan
-
Taipei Medical University WanFang HospitalUnknownCandidemia Prognostic Factor and Mycobiological Analysis.Taiwan
-
Fujian Shengdi Pharmaceutical Co., Ltd.Not yet recruitingPatients With Candidemia and/or Invasive Candidiasis
-
Centre Hospitalier Universitaire DijonUnknown
-
Karolinska University HospitalCompletedThe Value of Procalcitonin in Patients With Suspected CandidemiaSweden
-
AM-PharmaWithdrawn
-
Assistance Publique - Hôpitaux de ParisUnknownInfection, FungalFrance
-
Universidade Federal do Rio de JaneiroCompleted
-
T2 BiosystemsCompleted
Clinical Trials on Interferon Gamma-1B
-
Nantes University HospitalActive, not recruiting
-
National Cancer Institute (NCI)CompletedRecurrent Mycosis Fungoides and Sezary Syndrome | Refractory Mycosis Fungoides and Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIIA Mycosis... and other conditionsUnited States
-
Children's Hospital of PhiladelphiaFriedreich's Ataxia Research Alliance; Vidara Therapeutics Research LtdCompleted
-
InterMuneTerminated
-
InterMuneTerminatedPeritoneal Carcinoma | Ovarian CarcinomaUnited States
-
InterMuneTerminatedIdiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Lung DiseaseUnited States
-
InterMuneTerminatedIdiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Lung DiseaseUnited States
-
InterMuneCompletedPulmonary Fibrosis | Lung DiseaseUnited States
-
InterMuneCompletedCystic FibrosisUnited States
-
InterMuneCompleted